Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
194.89 | -1.88% | -3.73 |
MRTX closed down 1.88 percent on Monday, October 19, 2020, on 78 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bullish | Bullish Swing Setup | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | -1.88% | |
| New 52 Week High | Strength | -1.88% | |
| Upper Bollinger Band Walk | Strength | -1.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 3% | about 5 hours ago | |
| Outside Day | about 5 hours ago | |
| Fell Below Previous Day's Low | about 5 hours ago | |
| Down 2 % | about 6 hours ago | |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/02/2020
- Sector: Healthcare
- Industry: Biotechnology
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Medicine Biopharmaceutical Cancer Solid Tumors Chemical Compounds Oncology Lymphoma Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Medicine Biopharmaceutical Cancer Solid Tumors Chemical Compounds Oncology Lymphoma Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 203.77 |
| 52 Week Low | 66.01 |
| Average Volume | 424,583 |
| 200-Day Moving Average | 112.88 |
| 50-Day Moving Average | 157.39 |
| 20-Day Moving Average | 176.50 |
| 10-Day Moving Average | 187.90 |
| Average True Range | 8.24 |
| ADX | 44.19 |
| +DI | 33.52 |
| -DI | 9.69 |
| Chandelier Exit (Long, 3 ATRs ) | 179.05 |
| Chandelier Exit (Short, 3 ATRs ) | 179.44 |
| Upper Bollinger Band | 202.07 |
| Lower Bollinger Band | 150.93 |
| Percent B (%b) | 0.86 |
| BandWidth | 28.98 |
| MACD Line | 11.70 |
| MACD Signal Line | 10.27 |
| MACD Histogram | 1.4388 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 211.72 | ||||
| Resistance 3 (R3) | 212.81 | 208.29 | 208.92 | ||
| Resistance 2 (R2) | 208.29 | 204.00 | 207.75 | 207.98 | |
| Resistance 1 (R1) | 201.59 | 201.36 | 199.33 | 200.50 | 207.04 |
| Pivot Point | 197.07 | 197.07 | 195.94 | 196.53 | 197.07 |
| Support 1 (S1) | 190.37 | 192.78 | 188.11 | 189.28 | 182.74 |
| Support 2 (S2) | 185.85 | 190.14 | 185.31 | 181.80 | |
| Support 3 (S3) | 179.15 | 185.85 | 180.87 | ||
| Support 4 (S4) | 178.06 |
